Podcast Episodes

Back to Search
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs
ALS Advances Unite Patients and Pharma on Novel Targets, Biomarker Breakthroughs

In this episode, you'll be listening to Indu Navar, CEO and founder of EverythingALS and Dr. Olga Uspenskaya, chief medical officer at VectorY Therap…

4 months, 2 weeks ago

Short Long
View Episode
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval
Lilly Bests Novo Again, Rare Disease Week Goes Regulatory, More CDC Leadership Upheaval

Eli Lilly notches another win over Novo Nordisk, as Zepbound bests CagriSema in a head-to-head trial sponsored by Novo; The FDA kicked off Rare Disea…

4 months, 2 weeks ago

Short Long
View Episode
Corsera Eyes Two-Pronged Approach To Tackle Leading Cardiovascular Killer
Corsera Eyes Two-Pronged Approach To Tackle Leading Cardiovascular Killer

Corsera Health’s Chief Operating Officer Rena Denoncourt and CFO Meredith Kaya speak with BioSpace about the biotech’s mission and vision for the nex…

4 months, 2 weeks ago

Short Long
View Episode
Redefining Obesity Treatment Beyond GLP-1 Limits
Redefining Obesity Treatment Beyond GLP-1 Limits

In this episode, you'll be listening to Jane Hughes, President of R&D and Co Founder of Verdiva Bio, and Jon Rees, CEO and cofounder of MitoRx Therap…

4 months, 3 weeks ago

Short Long
View Episode
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders
Modernagate Fallout, Disc’s Rejection, Compass’ Psilocybin Data, CDC’s Lost Leaders

Last week, the FDA declined to review Moderna’s mRNA-based flu vaccine, with Center for Biologics Evaluation and Research Director Vinay Prasad himse…

4 months, 3 weeks ago

Short Long
View Episode
As FDA Moves Away From Animal Testing, AI and Organoids Can Shine
As FDA Moves Away From Animal Testing, AI and Organoids Can Shine

Last year, the FDA announced it would be phasingout animal testing requirements for some therapies. The NIHfollowed suit. According to Thomas Hartung…

4 months, 3 weeks ago

Short Long
View Episode
Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment
Digital Pathology, AI and the Future of ADCs and HER2 Cancer Treatment

In this episode of Denatured, Jennifer C. Smith-Parker speaks with Dr. Rob Monroe, Vice President and Chief Scientific Officer of Oncology at Danaher…

4 months, 4 weeks ago

Short Long
View Episode
Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News
Weight Loss Drama Compounds on Heels of Novo, Lilly Earnings, Plus Gene Therapy News

Last Thursday, Hims & Hers launched a compounded versionof Novo’s oral Wegovy, approved just before Christmas and launched in early January. Novo was…

4 months, 4 weeks ago

Short Long
View Episode
Programmable RNA 2.0: Beyond the First mRNA Revolution
Programmable RNA 2.0: Beyond the First mRNA Revolution

In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklud, CEO of Circio and Jacob Becraft, CO-founder and CEO of Strand Th…

5 months ago

Short Long
View Episode
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs

Pfizer reported the first data from its new obesity pipeline, picked up in the nearly $10 billion acquisition of Metsera last fall. While BMO Capital…

5 months ago

Short Long
View Episode

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us